医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Companion Diagnostics Market to Grow at 22.9% over the Next Decade, Predicts Roots Analysis

2014年06月05日 PM09:00
このエントリーをはてなブックマークに追加


 

LONDON

Roots Analysis has announced the addition of “Companion Diagnostics Market, 2014 – 2024 (2nd edition)” report to their offering. The study offers an extensive analysis of this growing market, including market forecasts for the period 2014-2024.

Shefali Asija, the principal analyst, said, “One of the key objectives of this report is to understand future evolution of the companion diagnostics market. Our proprietary ‘Companion Diagnostics Market Forecasting Model’ allows us to predict the growth of companion diagnostic tests across various parameters. The model, built over a ten year horizon, offers valuable insights on the global market evolution, regional variation, likely adoption of marketed/pipeline tests for specific biomarkers (e.g. EGFR, KRAS) and indications (e.g. metastatic non-small cell lung cancer, breast cancer).”

The report examines insights gathered from interviews of important stakeholders such as Qiagen and ResearchDx. Asija further stated, “Majority of our work is supported by detailed research. For the purposes of this report, we studied close to 100 deals/collaborations which have taken place since January 2011. The pipeline is rich; most products are being developed with the collaborative effort of pharmaceutical and diagnostics companies. We have discussed, in detail, the key drivers behind the regional and global growth. Apart from the US and Europe, the regional evaluation extends to other markets such as Japan, China and Australia. This provides a greater clarity on the differing approaches various regions have towards personalized medicine and companion diagnostics.”

Key topics covered in the report are:

  • Future market evolution (both in terms of number of tests and associated sales), split by biomarkers and specific indications
  • Regulatory landscape across regions
  • Recent deals and partnerships
  • Details on marketed and pipeline companion diagnostics
  • Case studies on leading companion drugs
  • Profiles of leading companies active in the market
  • Future growth opportunities for pharmaceutical and diagnostic companies

Who will benefit from this report?

The research is targeted towards healthcare professionals working in the field of diagnostics. In particular, you could benefit if you are an:

  • Investor
  • CXO Level Decision Maker
  • R&D Manager
  • Business Intelligence/Scientific Analyst
  • Business Development Manager
  • Finance Manager
  • Strategy Head

For additional details and/or to request sample pages, visit http://www.rootsanalysis.com/reports/view_document.html?report_id=60 or email sales@rootsanalysis.com.

CONTACT

Roots Analysis
Gaurav Chaudhary, +1-604-595-4954
gaurav.chaudhary@rootsanalysis.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結
  • 国際的な食品・飲料企業の連合が、世界の供給食料から人工トランス脂肪酸を排除するための世界保健機関とResolve to Save Livesによる呼び掛けを支持